Iclusig

Chemical Nameponatinib
Dosage FormTablet (oral; 10 mg, 15 mg, 30 mg, 45 mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyTakeda
Approval Year2012

Indication

  • For the treatment of chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors in adult patients
  • For the treatment of accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated in adult patients
  • For the treatment of T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL in adult patients
Last updated on 4/22/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Iclusig (ponatinib) Prescribing Information.2020Millennium Pharmaceuticals, Inc., Cambridge, MA
Document TitleYearSource
Chronic myeloid leukemia, version 2.2021.2020Journal of the National Comprehensive Cancer Network
Acute lymphoblastic leukemia, version 2.2021. 2020Journal of the National Comprehensive Cancer Network
Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.2017Annals of Oncology